BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617-679-2000
http://www.biogen.com

SectorHealthcare
SectorDrug Manufacturers—General
Empleados a tiempo completo7.800

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Michel VounatsosCEO & Director5,02MN/A1962
Mr. Jeffrey D. CapelloExec. VP & CFO1,59MN/A1965
Ms. Susan H. AlexanderExec. VP, Chief Legal Officer & Sec.1,81MN/A1957
Ms. Robin C. KramerVP & Chief Accounting OfficerN/AN/A1966
Mr. Mark J. HernonSr. VP & Chief Information OfficerN/AN/A1964
Los importes son a partir de 31 de diciembre de 2018 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Biogen Inc., a día 4 de octubre de 2019, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 5; Derechos de los accionistas: 2; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.
Al usar Yahoo aceptas que Yahoo y sus socios puedan utilizar cookies para personalización y otros fines